Alfresa deepens ReeNT tie-up with ¥600M bet on ear regeneration
What's the deal? Alfresa GroupDealroom has a profile for this one. Try Dealroom → has signed a new capital and business alliance with ReeNTDealroom has a profile for this one. Try Dealroom →, a research-driven startup spun out of Tokyo's Jikei University School of Medicine.
It will inject an additional ¥600 million, taking a 16.1% stake after the deal closed on May 27, 2026.
ReeNT is developing regenerative medicine for hard-to-treat ear, nose, and throat conditions. Its lead product, an autologous nasal mucosal epithelial cell sheet, uses a patient's own cells to regenerate middle-ear lining.
Why now? The two firms first partnered in 2024 to explore manufacturing and distribution. This deal moves them from exploration to commercialisation.
The cell sheet targets cholesteatoma, a condition where abnormal tissue destroys surrounding bone, causing hearing loss and, if untreated, meningitis or brain abscess. Surgery is currently the only treatment — and it strips away middle-ear lining, raising the risk of recurrence.
The underlying research has run for more than two decades at Jikei University.
What could go wrong? The product still needs clinical development, regulatory approval, and market launch in Japan. Alfresa says the deal will have only a minor impact on its 2026 earnings.
The funds will cover research, development, manufacturing, approval, and launch — a long road with no guaranteed payoff.
The signal: ReeNT remains an early-stage company, and Alfresa's move to lift its stake to 16.1% reflects a corporate investor willing to back unproven university science through to commercialisation. By plugging the startup into its "regenerative medicine total supply chain service," AlfresaDealroom has a profile for this one. Try Dealroom → is positioning itself to monetise the entire pathway — from cell materials to hospital delivery — rather than simply distributing a finished product.
Read more: PR Times
Image credit: pingnews.com
